SCHEMBL7208737

SCHEMBL7208737

O=C(Nc1ccc(Cl)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.67
KMT2A Q03164 7/20 0.67
MAPT P10636 6/20 0.67
LMNA P02545 5/20 0.67
SMN1; SMN2 Q16637 5/20 0.67
HTT P42858 5/20 0.65
RECQL P46063 3/20 0.65
POLB P06746 2/20 0.58
ALDH1A1 P00352 2/20 0.58
SLC10A6 Q3KNW5 2/20 0.58
SLC10A2 Q12908 1/20 0.58
SLC10A1 Q14973 1/20 0.58
PRSS12 P56730 1/20 0.52
F10 P00742 6/20 0.51
MCOLN3 Q8TDD5 1/20 0.51
CCR2 P41597 1/20 0.51
P2RX1 P51575 1/20 0.49
GPR27 Q9NS67 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7214479 0.91 SLC10A6 (0.72) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL492342 0.90 MEN1 (0.59) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL7120571 0.86 SMN1; SMN2 (0.65) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL10252896 0.85 ALDH1A1 (0.58) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL15627188 0.84 MEN1 (0.52) MEN1KMT2AMAPTLMNASMN1; SMN2
Ataciguat SCHEMBL29370450 0.84 KMT2A (0.64) MEN1KMT2AMAPTLMNASMN1; SMN2
Ataciguat SCHEMBL491675 0.84 KMT2A (0.64) MEN1KMT2AMAPTLMNASMN1; SMN2
Ataciguat SCHEMBL492158 0.83 KMT2A (0.63) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL15629754 0.83 MEN1 (0.55) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6754585 0.82 SLC10A6 (0.81) MEN1KMT2ALMNAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1187531-A4 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-05-28 EP claimed
US-6458845-B1 METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A SMITHKLINE BEECHAM CORPORATION 2002-10-01 US claimed
EP-1187531-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-20 EP claimed
WO-2001098264-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-27 WO claimed
WO-2000078145-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-28 WO claimed
EP-1187531-A4 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-05-28 EP disclosed
US-6458845-B1 METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A SMITHKLINE BEECHAM CORPORATION 2002-10-01 US disclosed
EP-1187531-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-03-20 EP disclosed
WO-2001098264-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-27 WO disclosed
WO-2000078145-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-28 WO disclosed